← All trials
NCT05076799
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- May 31, 2022
- Completion date
- Aug 31, 2022
- First posted
- Oct 13, 2021
- Last posted
- Oct 13, 2021
- Enrollment
- 1000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sichuan UniversityLead sponsor
- Sichuan UniversityReponsible party - principal investigator
- North Sichuan Medical UniversityCollaborator
- Southwest Medical UniversityCollaborator
- West China Medical UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.